KCNT1相关严重早发型癫痫的临床与分子特征
该研究对31例婴儿期迁移性局灶性癫痫(EIMFS)患者进行KCNT1基因筛查,并纳入其他早发型癫痫患者,发现12例携带KCNT1致病变异,其中4例为新变异;所有评估的KCNT1变异均导致功能获得,临床结局多数不良,奎尼丁仅1例有效。
要点
- KCNT1功能获得性变异可导致早发型严重局灶性癫痫谱系,包括EIMFS和早发型夜间额叶癫痫。
- 多数KCNT1变异为新发,基因型-表型关联尚不明确,但多数患者临床结局不良。
- 奎尼丁治疗反应不一,仅少数患者有效,需进一步探索靶向治疗。
核心结论
- KCNT1功能获得性致病变异可引起早发型严重局灶性癫痫谱系,多数病例临床结局不良。
研究设计与样本
- 研究纳入31例EIMFS患者进行KCNT1筛查(Sanger测序、多基因面板或全外显子测序),并纳入其他早发型癫痫患者。
- 对部分变异进行同源建模预测蛋白结构功能影响,并在非洲爪蟾卵母细胞模型中进行电生理评估。
主要发现
- 12例患者检出KCNT1致病变异,其中4例为新变异,多数变异为新发。
- 3例试用奎尼丁,1例临床反应良好。
- 计算建模提示异常孔道功能(F346L)和四聚体形成受损(F502V)为可能致病机制。
- 所有评估的KCNT1变异均导致显著功能获得,通道幅度增加,奎尼丁阻断作用不一。
临床怎么用
- 对早发型严重局灶性癫痫(尤其EIMFS)患者应考虑KCNT1基因检测。
- 奎尼丁可用于个别KCNT1相关癫痫患者,但疗效不一,需个体化评估。
局限性
- 基因型-表型关联尚不明确,需进一步研究。
- 奎尼丁治疗样本量小,疗效需更多证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the phenotypic spectrum, molecular genetic findings, and functional consequences of pathogenic variants in early-onset KCNT1 epilepsy. METHODS: We identified a cohort of 31 patients with epilepsy of infancy with migrating focal seizures (EIMFS) and screened for variants in KCNT1 using direct Sanger sequencing, a multiple-gene next-generation sequencing panel, and whole-exome sequencing. Additional patients with non-EIMFS early-onset epilepsy in whom we identified KCNT1 variants on local diagnostic multiple gene panel testing were also included. When possible, we performed homology modeling to predict the putative effects of variants on protein structure and function. We undertook electrophysiologic assessment of mutant KCNT1 channels in a xenopus oocyte model system. RESULTS: We identified pathogenic variants in KCNT1 in 12 patients, 4 of which are novel. Most variants occurred de novo. Ten patients had a clinical diagnosis of EIMFS, and the other 2 presented with early-onset severe nocturnal frontal lobe seizures. Three patients had a trial of quinidine with good clinical response in 1 patient. Computational modeling analysis implicates abnormal pore function (F346L) and impaired tetramer formation (F502V) as putative disease mechanisms. All evaluated KCNT1 variants resulted in marked gain of function with significantly increased channel amplitude and variable blockade by quinidine. CONCLUSIONS: Gain-of-function KCNT1 pathogenic variants cause a spectrum of severe focal epilepsies with onset in early infancy. Currently, genotype-phenotype correlations are unclear, although clinical outcome is poor for the majority of cases. Further elucidation of disease mechanisms may facilitate the development of targeted treatments, much needed for this pharmacoresistant genetic epilepsy.
引用
- McTague A, Nair U, Malhotra S, et al. Clinical and molecular characterization of KCNT1-related severe early-onset epilepsy. Neurology. 2017. PMID: 29196579. doi:10.1212/WNL.0000000000004762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。